Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
1998 5
1999 1
2000 1
2001 1
2005 2
2006 1
2007 1
2009 1
2010 1
2011 1
2013 1
2014 1
2018 1
2019 1
2023 1
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.
Fierer DS, Dieterich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, van Seggelen WO, Hijdra RM, Cassagnol DG; New York Acute Hepatitis C Surveillance Network. Fierer DS, et al. Clin Infect Dis. 2014 Mar;58(6):873-9. doi: 10.1093/cid/cit799. Epub 2013 Dec 13. Clin Infect Dis. 2014. PMID: 24336914 Free PMC article. Clinical Trial.
Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience.
McGuirk M, Shahzad M, Amin MK, Khan MA, Bellman P, Mudaranthakam DP, DeJarnette S, Lutfi F, Ahmed N, Bansal R, Abdelhakim H, Gorsline C, Shoemaker DM, Abdallah AO, Shune L, Abhyankar SH, Singh AK, McGuirk JP, Mushtaq MU. McGuirk M, et al. Among authors: bellman p. Transpl Immunol. 2024 Jun;84:102039. doi: 10.1016/j.trim.2024.102039. Epub 2024 Mar 19. Transpl Immunol. 2024. PMID: 38513813 Free article.
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Towner W, Lalezari J, Sension MG, Wohlfeiler M, Gathe J, Appelbaum JS, Bellman P, Gottlieb MS, Ryan R, Nijs S, Hoogstoel A, Van Solingen-Ristea R, Witek J. Towner W, et al. Among authors: bellman p. J Acquir Immune Defic Syndr. 2010 Apr;53(5):614-8. doi: 10.1097/QAI.0b013e3181cdebb1. J Acquir Immune Defic Syndr. 2010. PMID: 20134329 Clinical Trial.
25 results